Referências:
 
LBA500:
 Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant
treatment in patients with HR+/HER2− early breast cancer. 
 
LBA506: 3-year invasive disease-free
survival (iDFS) of the strategy-based, randomized phase II PHERGain trial
evaluating chemotherapy (CT) de-escalation in human epidermal growth factor
receptor 2-positive (HER2[+]) early breast cancer (EBC).
 
--

Referências: LBA500: Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer. LBA506: 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). --

Referências:
&nbsp;
LBA500:
&nbsp;Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant
treatment in patients with HR+/HER2− early breast cancer. 
&nbsp;
LBA506:&nbsp;3-year invasive disease-free
survival (iDFS) of the strategy-based, randomized phase II PHERGain trial
evaluating chemotherapy (CT) de-escalation in human epidermal growth factor
receptor 2-positive (HER2[+]) early breast cancer (EBC).
&nbsp;
--

Câncer de mama no ASCO 2023

Podcast do portal onconews.com.br
destinado a oncologistas e médicos de outras especialidades envolvidos na prevenção, no diagnóstico e no tratamento do câncer.

Medicine

Health & Fitness

Podcast do portal onconews.com.br destinado a oncologistas e médicos de outras especialidades envolvidos na prevenção, no diagnóstico e no tratamento do câncer.

Share Câncer de mama no ASCO 2023

Sign up to save your podcasts

Câncer de mama no ASCO 2023

Câncer de mama no ASCO 2023